# To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)

> **NCT03622008** · PHASE1 · COMPLETED · sponsor: **Wockhardt** · enrollment: 20 (actual)

## Conditions studied

- Antibiotics Causing Adverse Effects in Therapeutic Use

## Interventions

- **DRUG:** FEP-TAZ 4 g
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03622008
- **Lead sponsor:** Wockhardt
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-23
- **Primary completion:** 2018-05-13
- **Final completion:** 2018-05-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622008, "To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03622008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*